Snyman L, Venables E, Trivino Duran L, Mohr E, Azevedo VD, et al.
2018-09-01 • International Journal of Tuberculosis and Lung Disease
2018-09-01 • International Journal of Tuberculosis and Lung Disease
SETTING Early interventions for patients who interrupt their treatment for drug-resistant tuberculosis (DR-TB) are rarely reported and assessed. A novel, patient-centred intervention...
Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF, et al.
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Ferlazzo G, Mohr E, Laxmeshwar C, Hewison CCH, Hughes J, et al.
2018-02-13 • Lancet Infectious Diseases
2018-02-13 • Lancet Infectious Diseases
BACKGROUND Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients ...
Ndjeka N, Schnippel K, Master I, Meintjes GA, Maartens G, et al.
2018-10-25 • European Respiratory Journal
2018-10-25 • European Respiratory Journal
Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a ...
Mohr E, Snyman L, Mbakaz Z, Caldwell J, De Azevedo V, et al.
2018-09-14 • PLOS One
2018-09-14 • PLOS One
BACKGROUND Self-administered treatment (SAT), a differentiated model of care for rifampicin-resistant tuberculosis (RR-TB), might address adherence challenges faced by patients and h...
Mohr E, Daniels J, Beko B, Isaakidis P, Cox V, et al.
2017-05-18 • PLOS One
2017-05-18 • PLOS One
BACKGROUND Daily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administer...
Mohr E, Ferlazzo G, Hewison CCH, De Azevedo V, Isaakidis P
2019-05-01 • Lancet Infectious Diseases
2019-05-01 • Lancet Infectious Diseases
Here we report on the final outcomes for the cohort of 28 patients from Armenia, India, and South Africa who initiated regimens containing the combination of bedaquiline and delamanid fr...
Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, et al.
2018-05-03 • European Respiratory Journal
2018-05-03 • European Respiratory Journal
Experience with delamanid (Dlm) is limited, particularly among HIV-positive individuals. We describe early efficacy and safety data from a programmatic setting in South Africa. This was ...
Berhanu R, Schnippel K, Mohr E, Hirasen K, Evans D, et al.
2016-11-03 • PLOS One
2016-11-03 • PLOS One
OBJECTIVE: We describe baseline characteristics, time to treatment initiation and interim patient outcomes at a decentralized, outpatient treatment site for rifampicin-resistant TB (RR-T...
Hughes J, Reuter A, Chabalala B, Isaakidis P, Cox HS, et al.
2019-09-01 • International Journal of Tuberculosis and Lung Disease
2019-09-01 • International Journal of Tuberculosis and Lung Disease
SETTING: Patients with rifampicin-resistant tuberculosis (RR-TB) in the township of Khayelitsha, South Africa, were offered delamanid (DLM) within a decentralised RR-TB treatment program...
Mohr E, Daniels J, Muller O, Furin J, Chabalala B, et al.
2017-10-01 • International Journal of Tuberculosis and Lung Disease
2017-10-01 • International Journal of Tuberculosis and Lung Disease
OBJECTIVE To assess the proportion of rifampicin-resistant tuberculosis (RR-TB) patients with potential earlier RR-TB diagnoses in Khayelitsha, South Africa.
